Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus LIPIODOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus LIPIODOL.
IOPAMIDOL-200 IN PLASTIC CONTAINER vs LIPIODOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Lipiodol is an iodinated ethyl ester of the fatty acids of poppyseed oil. It acts as a radiopaque contrast agent for imaging due to its iodine content, and in chemoembolization, it selectively accumulates in hepatocellular carcinoma (HCC) via tumor neovasculature and is retained due to lack of lymphatic drainage, allowing targeted delivery of chemotherapeutic agents.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
Lymphangiography: 5-20 mL injected slowly into lymphatic vessels. Uterine/Fallopian tube imaging: 3-20 mL injected through cervix. Hepatic chemoembolization: 5-15 mL mixed with chemotherapeutic agents injected into hepatic artery.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 50-60 days, reflecting slow clearance from lipid-rich tissues.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Primarily eliminated via biliary/fecal route as unchanged drug; less than 1% excreted renally.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent